Jeffrey A. Lieberman, M.D.

Printer-friendly versionPrinter-friendly version
Jeffrey A. Lieberman, M.D.

JOINED THE SCIENTIFIC COUNCIL IN 2001

Lawrence C. Kolb Professor and Chairman,
Department of Psychiatry
Lieber Chair for Schizophrenia Research
Columbia University College of Physicians and Surgeons
Director, New York State Psychiatric Institute
Psychiatrist-in-Chief, NewYork-Presbyterian Hospital, Columbia
University Medical Center

Dr. Lieberman’s work has advanced our understanding of the natural history and pathophysiology of schizophrenia and the pharmacology and clinical effectiveness of antipsychotic drugs.  In terms of the latter, he served as Principal Investigator of the Clinical Antipsychotic Trials of Intervention Effectiveness Research Program (CATIE), sponsored by the NIMH.  He also currently serves as Principal Investigator on the newly awarded NIMH contract Recovery After an Initial Schizophrenic Episode (RAISE) and will lead a multi-institution research team in developing and testing an evidence-based strategic intervention for early psychosis to demonstrate how treatment at the onset of symptoms can prevent the debilitating effects of schizophrenia and related psychotic disorders.

Dr. Lieberman has been at Columbia University since 2005. Previously, he was Thad and Alice Eure Distinguished Professor of Psychiatry, Pharmacology and Radiology, and vice chairman for research and scientific affairs at the University of North Carolina at Chapel Hill School of Medicine, and on the faculties of the Albert Einstein College of Medicine and the Mount Sinai School of Medicine.

A member of NARSAD’s Scientific Council since 2001, Dr. Lieberman received a NARSAD Distinguished Investigator Award in 1999 and 2008, and is the 2006 recipient of NARSAD’s Lieber Prize for Outstanding Achievement in Schizophrenia Research.  Dr. Lieberman noted, “The scientific community owes a huge debt of gratitude to NARSAD, which has set the world standard for support of mental illness research by the private sector. Virtually every successful scientist in the psychiatric research community has had their work and careers touched by NARSAD in so many beneficial ways.”

NARSAD Grants: Distinguished Investigator 1999 and 2007

Foundation Prizes: 2006 Lieber Prize for Outstanding Achievement in Schizophrenia Research